Evidence map›Paper›PMID 42313099›Full record

ArticleAntimicrobial agents and chemotherapy2026

Intrinsic resistance networks shape cefiderocol susceptibility in ST258

Kevin J Rome, Austin J Terlecky, Kelly K Yen, Tengfei Long, Mia J Bucich, Klara V Thom, Elena Shashkina, Liang Chen, Barry N Kreiswirth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kevin J Rome *Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-2262-4813
Austin J Terlecky *Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0009-0005-8209-8922
Kelly K YenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Tengfei LongSchool of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Mia J BucichCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Klara V ThomCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Elena ShashkinaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Liang ChenSchool of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-5845-2235
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0243-131X

Funding

NIH HHS 1R01AI87297-01A1
6 · The paper itself

Abstract

Cefiderocol (CFDC) is a siderophore-conjugated cephalosporin developed to overcome multidrug resistance in gram-negative bacteria. Despite its unique iron-dependent entry mechanism, CFDC resistance has emerged in

Indexed as

Anti-Bacterial AgentsCephalosporinsKlebsiella pneumoniaeBacterial Proteinsbeta-LactamasesCefiderocolDNA Transposable ElementsDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsSiderophoresAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCefiderocolCephalosporinsDNA Transposable ElementsSiderophorescefiderocolCirAECAenvelope stressKlebsiella pneumoniaeKPCpeptidoglycanST258Tn-SeqTonB

Identifiers

PMID42313099
PMCPMC13436387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.